XRD-0394

N/A

Report date: 2025/02/28 14:32:35
NMEFirst In Class

Base Information

Drug NameXRD-0394
Drug Alias NameXRD-0394
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATM inhibitorsDNA-dependent protein kinase inhibitors
TargetsSerine-protein kinase ATMDNA-dependent protein kinase
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisGlioma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXrad Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNyu Langone HealthXrad Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisGlioma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A